Skip to main content
OpenTrials
Completed

NCT Number: NCT01973478

Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression

Major depressive disorders are real public health issues in terms of diagnosis and treatment. Some forms of depression are chronic and resistant to treatment (TRD). In these forms suicide risk is important.

Patients with TRD are potential candidates for neurosurgical interventions to treat depression. However, psychosurgery interventions based upon lesions, showed their limitations related to 1. the large variability in neurosurgical gestures, 2. their side effects, and of course 3. the irreversible damage caused by the surgery.

Thus, deep brain stimulation (DBS) could represent an opportunity for patients suffering from TRD. Our preliminary study based upon the stimulation of the accumbens nucleus showed encouraging results. The investigators have thus planned a randomized controlled trial versus sham stimulation to confirm the therapeutic value of nucleus accumbens DBS.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

APHM, Marseille, France

Loading trial locations.

About this study

Because of their recurrent nature, their prevalence and their consequences, major depressive disorders are real public health issues in terms of diagnosis and treatment.

Some forms of depression are chronic and resistant to treatment (TRD), either unipolar (repeated episodes of depression) or bipolar (repeated episodes of depression and manic and/or hypomanic episodes). In these forms suicide risk is important.

Patients with TRD are potential candidates for neurosurgical interventions to treat depression. The benefit of neurosurgical procedures is expected to be important in these patients.

Psychosurgery interventions based upon lesions, however, showed their limitations related to 1/ the large variability in neurosurgical gestures, 2/ their side effects, and of course 3/ the irreversible damage caused by the surgery.

Current brain imaging data yielded fresh information about the pathophysiology of depression and suggested new therapeutic approaches in TRD.

Modulation of sub-caudate specific pathways, which are part of orbitofrontal and anterior cingulate cortico-subcortical loops should allow for a diminution of depressive symptoms.

The modulation of these specific pathways, initially targeted by classical neurosurgery, could benefit from current developments in functional neurosurgery.

Deep brain stimulation (DBS) may represent an opportunity for patients suffering from TRD. Our preliminary study based upon the stimulation of the accumbens nucleus showed encouraging results. The investigators have thus planned a randomized controlled trial versus sham stimulation to confirm the therapeutic value of nucleus accumbens DBS.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 70 years
  • DSM-IV (DSM = Diagnostic and Statistical Manual) criteria for a recurrent depressive disorder or bipolar disorder
  • Duration of the episode > 2 years
  • Severity of the episode attested by :
  • A HDRS score > 21
  • A CGI score ≥ 4
  • A GAF < 50
  • Persistence of severity criteria during the screening
  • Following characteristics resistance in case of recurrent depressive disorder :
  • Stage V of the classification of Thase and Rush
  • Unsuccessful treatment by the association of two antidepressants (or intolerance/contra-indications)
  • Unsuccessful treatment by the association for at least 6 weeks of one of the following treatments : lithium , thyroid hormone , buspirone , pindolol with an antidepressant (or intolerance/contra-indications)
  • Unsuccessful treatment by the combination of a second-generation antipsychotic (olanzapine, risperidone, amisulpride, aripiprazole, clozapine and quetiapine) to an antidepressant (or intolerance/contra-indications)
  • Unsuccessful treatment by a structured psychotherapy
  • Following characteristics of resistance in case of bipolar disorder:
  • Unsuccessful treatment by lithium (or intolerance/contra-indications)
  • Unsuccessful treatment by at least one mood stabilizer anticonvulsant (or intolerance/contra-indications)
  • Unsuccessful treatment by at least one second-generation antipsychotic (or intolerance/contra-indications)
  • Unsuccessful treatment by the combination of two mood stabilizers with at least an anticonvulsant (or intolerance/contra-indications)
  • Unsuccessful treatment by electro-convulsive therapy sessions (or intolerance/contra-indications)
  • Unsuccessful treatment by at least one antidepressant , mood stabilizer combination (or intolerance/contra-indications)
  • Unsuccessful treatment by a structured psychotherapy
  • Understanding the conduct of the study
  • Giving a written informed consent
  • Benefiting from the french social insurance

Non-Inclusion Criteria:

  • Comorbid axis 1 disorder (except dysthymia, generalized anxiety disorder, social phobia, panic disorder)
  • Alcohol or other psychoactive substances dependence (except nicotine)
  • Suicidal risk during the last month assessed by the MINI (Mini International Neuropsychiatric Interview), the DIGS (Diagnostic Interview for Genetic Studies) and the item 3 of the HDRS
  • Suicide attempt in the last 6 months or two suicide attempts in the previous two years
  • History of forensic act or furious mania
  • Depressive episode with congruent or incongruent psychotic features or history of a depressive episode with psychotic features
  • Comorbid cluster A or B personality disorders according to the DSM IV-TR evaluated using the SCID2 (Structured Clinical Interview for DSM-IV)
  • Cognitive Impairment (Mattis < 130)
  • MRI (Magnetic Resonance Imaging) contraindication to stimulation or contraindications for MRI
  • Major somatic disease making it impossible to set up the study treatment
  • Pregnant women, or nursing or childbearing potential without effective contraception
  • Involuntary commitment
  • Guardianship
  • Participation in another study

Treatment and study plan

DBS

Device

SHAM

Device

Primary outcomes

  1. Response = 50 % decrease of the HDRS-17 (Hamilton depression rating scale, 17 items version) (yes/no)

    Time frame: Month 7

    Response is defined as a 50 % decrease of the HDRS-17 (Hamilton depression rating scale, 17 items version)

Secondary outcomes

  1. Remission (yes/no)

    Time frame: Month 7

    Remission is defined as an HDRS-17 score < 7

  2. CGI (Clinical global impressions) amelioration (yes/no)

    Time frame: Month 7

    Score of 1 or 2 (item 2 of the CGI)

  3. GAF (Global assessment of functioning)

    Time frame: Month 7

    Presence of a score ≥ 60

  4. HDRS-17 (Hamilton depression rating scale, 17 items version)

    Time frame: Month 7

    Score

  5. MADRS (Montgomery-Asberg Depression Rating Scale)

    Time frame: Month 7

    Score

  6. BDI (Beck Depression Inventory)

    Time frame: Month 7

    Score

  7. CGI (Clinical global impressions)

    Time frame: Month 7

    Score

  8. LARS (Lille Apathy Rating scale)

    Time frame: Month 7

    Score

  9. GAF (Global assessment of functioning)

    Time frame: Month 7

    Score

  10. Neuropsychological assessment

    Time frame: Day -7 ; Month 1; Month 7; Month 13; Month 19; Month 24

  11. Cerebral metabolism (PET scans)

    Time frame: Day -7; Month 7

  12. Adverse events

    Time frame: Month 24

    Adverse events occuring during the study.

Other outcomes

  1. HDRS-17 (Hamilton depression rating scale, 17 items version)

    Time frame: Month -3 ; Month -1; Day -7; Day 15; Month 1; Day 45; Month 2 ; Day 75 ; Month 3; Month 4; Month 5; Month 6; Month 7; Month 8; Month 9; Month 10; Month 13; Month 16; Month 19; Month 22; Month 24

    Longitudinal evolution of the score

  2. MADRS (Montgomery-Asberg Depression Rating Scale)

    Time frame: Month -3 ; Month -1; Day -7; Day 15; Month 1; Day 45; Month 2 ; Day 75 ; Month 3; Month 4; Month 5; Month 6; Month 7; Month 8; Month 9; Month 10; Month 13; Month 16; Month 19; Month 22; Month 24

    Longitudinal evolution of the score

  3. BDI (Beck Depression Inventory)

    Time frame: Day -7; Day 15; Month 1; Day 45; Month 2 ; Day 75 ; Month 3; Month 4; Month 5; Month 6; Month 7; Month 8; Month 9; Month 10; Month 13; Month 16; Month 19; Month 22; Month 24

    Longitudinal evolution of the score

  4. CGI (Clinical global impressions)

    Time frame: Month -3 ; Month -1; Day-7; Day15; Month 1; Day 45; Month 2 ; Day 75 ; Month 3; Month 4; Month 5; Month 6; Month 7; Month 8; Month 9; Month 10; Month 13; Month 16; Month 19; Month 22; Month 24

    Longitudinal evolution of the score

  5. LARS (Lille Apathy Rating scale)

    Time frame: Day -7; Month 1; Month 7; Month 13; Month 19; Month 24

    Longitudinal evolution of the score

  6. GAF (Global assessment of functioning)

    Time frame: Month -3 ; Month -1; Day -7; Month 1; Month 7; Month 13; Month 19; Month 24

    Longitudinal evolution of the score

  7. YMRS (Young Mania Rating Scale)

    Time frame: Day -7; Month 1; Month 7; Month 13; Month 19; Month 24

    Longitudinal evolution of the score

  8. MATHYS (Multidimensional Assessment of Thymic States)

    Time frame: Day -7; Month 1; Month 7; Month 13; Month 19; Month 24

    Longitudinal evolution of the score

  9. Response (50 % decrease of the HDRS-17)

    Time frame: Month 24

    During the whole follow up

  10. Remission

    Time frame: M24

    During the whole follow up Remission is defined as an HDRS-17 score < 7

Sponsors and collaborators

Lead sponsor

Rennes University Hospital

Other

Registry information

Acronym: STHYM

Important dates

Study start
2014
Primary completion
2017
Study completion
2018
First posted
Oct 31, 2013
Registry last updated
Dec 27, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.